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Abstract
Background: Deep-sequencing allows for an in-depth characterization of sequence variation in complex
populations. However, technology associated errors may impede a powerful assessment of low-frequency mutations.
Fortunately, base calls are complemented with quality scores which are derived from a quadruplet of intensities, one
channel for each nucleotide type for Illumina sequencing. The highest intensity of the four channels determines the
base that is called. Mismatch bases can often be corrected by the second best base, i.e. the base with the second
highest intensity in the quadruplet. A virus variant model-based clustering method, ViVaMBC, is presented that
explores quality scores and second best base calls for identifying and quantifying viral variants. ViVaMBC is optimized
to call variants at the codon level (nucleotide triplets) which enables immediate biological interpretation of the
variants with respect to their antiviral drug responses.
Results: Using mixtures of HCV plasmids we show that our method accurately estimates frequencies down to 0.5%.
The estimates are unbiased when average coverages of 25,000 are reached. A comparison with the SNP-callers
V-Phaser2, ShoRAH, and LoFreq shows that ViVaMBC has a superb sensitivity and specificity for variants with
frequencies above 0.4%. Unlike the competitors, ViVaMBC reports a higher number of false-positive findings with
frequencies below 0.4% which might partially originate from picking up artificial variants introduced by errors in the
sample and library preparation step.
Conclusions: ViVaMBC is the first method to call viral variants directly at the codon level. The strength of the
approach lies in modeling the error probabilities based on the quality scores. Although the use of second best base
calls appeared very promising in our data exploration phase, their utility was limited. They provided a slight increase in
sensitivity, which however does not warrant the additional computational cost of running the offline base caller.
Apparently a lot of information is already contained in the quality scores enabling the model based clustering
procedure to adjust the majority of the sequencing errors. Overall the sensitivity of ViVaMBC is such that technical
constraints like PCR errors start to form the bottleneck for low frequency variant detection.
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Background
In a virology research environment, the study of viral
quasispecies in infected patients is essential for under-
standing pathways to resistance and can substantially
improve treatment. Genotypic and phenotypic methods
are commonly used for detecting antiviral resistance
in clinical HIV-1 and HCV specimens. Standard geno-
typing such as direct PCR sequencing methods, how-
ever, only provides information on the most abundant
sequence variants. Modern massive parallel sequencing
(MPS) technologies, on the contrary, have the opportunity
to allow in-depth characterization of sequence variation
in more complex populations, including low-frequency
viral strains. However, one of the challenges in the detec-
tion of low-frequency viral strains concerns the errors
introduced during the sequencing process. As these spe-
cific errors may occur at equal or even higher frequencies
than true biological mutations, a powerful assessment of
low-frequency virus mutations is seriously jeopardized
[1,2].
Many proposals have been made to address this chal-
lenge of decreased detection power. Several authors com-
pared the distribution of variants to Poisson, binomial or
beta-binomial error distributions [3-7]. They all, however,
assume that base calls are of equal quality which is not the
case in MPS [8,9]. As a potential solution other authors
suggested to incorporate quality scores when modeling
the error distribution [10-13]. Many of these methods
focus primarily on 454 data [3-6,11,13]. The announce-
ment by Roche to fade out the 454 technology by mid
2016, illustrates the pressing need to focus on alternative
technologies [14]. Moreover, the incorporation of quality
scores is most appropriate for Illumina sequencing data.
Illumina quality scores reflect the base calling substitution
error probabilities [15], whereas 454 quality scores do not
have such an intuitive interpretation [16]: they represent
the probability of calling a homopolymer up to a particular
length.
Illumina’s sequencing technology is a sequencing-by-
synthesis technology where the DNA fragments are syn-
thesized one base at a time. The DNA fragments to
be sequenced are first spatially separated and ampli-
fied, resulting in clusters of identical sequences on the
sequencing flow cell. Identification of different bases in
the sequencing-by-synthesis process is enabled by using
distinct fluorophores for each nucleotide type (A,C,T,G).
At every sequencing cycle a single labeled 3’-blocked
nucleotide is incorporated to the complementary strand
of each DNA fragment. The fluorophore is determined
with imaging technology using four different fluorescence
channels, one for each nucleotide type. For every frag-
ment in each cycle, the base caller assigns the nucleotide
that corresponds with the highest intensity among the
four channels. A correct base identification is complicated
by multiple effects. On the one hand, emission spectra of
the fluorophores are overlapping, especially the A and C
intensities and the G and T intensities. On the other hand,
phasing and pre-phasing describes the loss of synchrony
of the sequence copies of a cluster. Phasing is caused by
incomplete removal of the 3′-protecting groups resulting
in sequences within clusters lagging behind in the incor-
poration cycle. Pre-phasing is caused by the incorporation
of nucleotides without effective 3′-protecting groups. This
can cause incorporation of multiple bases in each cycle
and might hamper a correct interpretation of the intensi-
ties. Quality scores are derived from the intensities [17].
From literature [18] and own experiments it is clear that
these quality scores often underestimate the true error
probabilities. Extra information which can be used in this
context is the second best base calls, which are the bases
corresponding to the second highest intensity. Abnizova
et al. [19] observed that a mismatch base could often
be corrected by its second best base call. In an exper-
iment with known reference sequence 722,505 codons
were evaluated of which 34,644 were errors (≈5%). Sev-
enty percent of these errors could be corrected by the
second best base calls (see later for more details). Hence,
we will explore the utility of second best base calls in
addition to the quality scores within a new variant calling
algorithm.
Here we propose Virus Variant Model-Based Cluster-
ing (ViVaMBC), a method that models error probabilities
of the best and second best base calls as a function of
the Illumina quality scores. These error probabilities are
embedded in a multinomial mixture so that viral variants
can be identified and quantified. This paper will illus-
trate and validate this method using read sets with known
variation and evaluate the minimum sequencing depth.
Its performance will be empirically compared with three
other methods (LoFreq [10], V-Phaser2 [12] and ShoRAh
[5]). Finally, we will demonstrate ViVaMBC on a clinical
HCV sample.
Methods
Experiments
Several samples from HCV-infected patients as well as
HCV plasmids were paired-end sequenced using Illu-
mina’s genome analyzer(GA)IIx according to manufac-
turing protocols. A detailed description of the data and
protocols is given in Thys et al. (Thys K, Verhasselt
P, Reumers J, Verbist BMP, Maes B, Aerssens J. Per-
formance assessment of the Illumina massively parallel
sequencing platform for deep sequencing analysis of viral
minority variants, submitted). The sequencing images
are converted into reads using Illumina’s off-line base
caller (OLB) [20]. In contrast to the standard workflow,
using real time analysis (RTA), the OLB can also pro-
vide second best base calls which are explored for an
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improved error correction. In the next steps reads are
aligned against a consensus sequence using BWA [21].
The resulting bam files are adapted using GATK clipReads
to prevent trimming of the data, and all reads contain-
ing indel errors are removed (workflow presented in
Additional file 1). It is hereby assumed that indels will
result in non-viable viruses. These bam files are used
as input of ViVaMBC which is explained in the next
section.
Model-based clustering
Let ri denote the vector with the best base calls of read i,
with i ranging from 1 to n. Similarly, si denotes the vec-
tor with the second best base calls of read i. The vector
with the corresponding error probabilities is denoted as
θri and θsi for best and second best base calls respectively.
A dummy variable Pairi is introduced to indicate which
end of the DNA segment is sequenced in the paired-end
sequencing strategy: Pairi equals 1 if read i is first in
pair and 0 otherwise. In case of single-end experiments
the variable Pairi can simply be omitted from the model.
The library of reads represent the whole viral population
consisting of several viral subspecies.
The variant calling is applied locally. Upon read align-
ment the vectors ri are retained that cover a small window
of the reference sequence under investigation. To avoid
the challenges involved in inferring haplotypes beyond the
actual read lengths [22], only windows smaller than the
read length are considered. Let m denote the length of
the window; thus rti = (ri1, . . . , rim), APi denote the aver-
age quality score of read i in window m and θoil with l =
(1, . . . ,m) denotes the probability that the lth nucleotide
from read i differs from ril or sil.
Suppose that k variants of length m exist with variant
sequences given by the vectors h1, . . . ,hk . Let τj denote
the prior probability that a read originates from variant j
(j = 1, . . . , k). They have the interpretation of relative fre-
quencies of the viral variants within the window, which are
the key parameters of interest inferred from the observed
data.
The likelihood of the observed data has the natural
interpretation of a mixture model with k components that
refer to the true variants. The likelihood is the product
of the probabilities that a read was generated from the
mixture of variants with relative frequencies τj:
L =
n∏
i=1
f (ri, si) =
n∏
i=1
⎡⎣ k∑
j=1
τj fj(ri, si)
⎤⎦ , (1)
where f denotes a generic density function and fj is the
probability of observing best calls ri and second best calls
si when read i belongs to variant j. Upon relying on the
multinomial distribution, the probability fj can be written
as
fj(ri, si) =
m∏
l=1
fj(ril, sil)
=
m∏
l=1
θ
I
(
ril=hjl
)
ril θ
I
(
sil=hjl
)
sil θ
(
1−I(ril=hjl))(1−I(sil=hjl))
oil ,
(2)
in which I(A) = 1 if A is true, and I(A) = 0 other-
wise. Note, however, that the probabilities θril, θsil and θoil
can not be estimated from the data because the model
is over-identified (two parameters for each observation).
We therefore model the θ parameters as a function of the
quality scores of the best base calls (Pril), a dummy vari-
able Pair (Pairi ), and the average quality score (APi). For
each location l, the θ ’s refer to a multinomial distribution
with three classes for which we suggest amultinomial logit
model
log θcil
θoil
= β0c + β1cPril + β2cPairi + β3cAPi, (3)
with c ∈ {r, s}. For paired-end experiments eight β param-
eters need to be estimated together with the variant
sequences hj (j = 1, . . . , k) and the relative frequen-
cies τj. For single-end experiments two β parameters are
removed since the Pairi variable can be omitted. To infer
the true variants and their frequencies the log likelihood
l =
n∑
i=1
log
⎡⎣ k∑
j=1
(
τj
m∏
l=1
θ
I
(
ril=hjl
)
ril θ
I
(
sil=hjl
)
sil θ
(
1−I(ril=hjl))(1−I(sil=hjl))
oil
)⎤⎦ ,
(4)
after substituting the θ-parameters with (3) will be maxi-
mized. However, as closed form solutions for τj, hj and β
are not available, numerical methods were implemented
for direct maximization of the log likelihood (4). The EM
algorithm is a popular alternative for maximizing mix-
ture distributions [23,24]. It requires the introduction of
latent or ’missing’ indicator variables zij which are 1 when
read i belongs to variant j and zero otherwise. Note that
zi = (zi1, . . . , zik)t are multinomial distributed with den-
sity g(zi) and P(zij = 1) = τj. Hence the likelihood (1) can
be augmented
L =
n∏
i=1
f (ri, si, zi) =
n∏
i=1
f (ri, si|zi)g(zi) =
n∏
i=1
k∏
j=1
(
fj(ri, si)τj
)zij ,
(5)
which in turn allows an efficient factorization by condi-
tioning on zi. In particular, given I(r)ijl = I(ril = hjl) and
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I(s)ijl = I(sil = hjl), the complete data log-likelihood lc can
be written as
lc =
n∑
i=1
k∑
j=1
zij
{
log τj +
m∑
l=1
[
I(r)ijl log θril + I(s)ijl log θsil
+
(
1 − I(r)ijl
) (
1 − I(s)ijl
)
log θoil
]}
,
(6)
in which the θ parameters have to be substituted with (3).
The EM algorithm iterates over an expectation (E) and a
maximization (M) step until convergence.
1. E step: Computation of the expected complete data
log-likelihood (6), given the observed data and the
current parameter estimates. The solution is given by
(6) with zij replaced by
ẑij = E(zij | ri, si) =
τ̂j fj
(
ri, si|ĥj, β̂
)
∑k
l=1 τ̂l fl
(
ri, si|ĥj, β̂
) (7)
where fj depends on ĥj and the β̂ parameter
estimates from the previous M-step.
2. M step: Maximization of the expected complete data
log-likelihood from the E-step with respect to τ , h,
and β parameters. This results in updated parameter
estimates. In particular
•
τ̂j =
∑n
i=1 ẑij
n (8)
• hj is the most abundant sequence among those
with maximal ẑij across the variants
(j = 1, . . . , k).
• β parameter estimates are obtained by fitting
the multinomial regression model (3) using the
ẑij as weights.
The EM algorithm is initialized with k variants (as a
default k is set to 10). The kth most observed variants are
taken as initial variant sequences hj (j = 1, . . . , k). These
variants are updated in each M-step. A variant j will dis-
appear if no sequences are attributed to cluster j. Upon
convergence, the number of variants k and their final esti-
mates of τj and hj define the variant population in the
window of sizem.
The method is optimized for window size m = 3,
codon level, to retain linkage information between single-
nucleotide polymorphisms. These codons facilitate the
biological interpretation in the coding regions of the virus.
Since resistance-associated mutations against antiviral
drugs are particularly of interest, drug-target regions
within viral protein coding regions will be investigated.
Hence, the reported codon variants can be interpreted
immediately with respect to their antiviral drug responses.
ViVaMBC is implemented in R and parallelized. Each win-
dow of interest can be run on a different core, thereby
speeding up the performance. Approximately, one posi-
tion runs for 1 hour when coverages around 60,000 are
reached and m = 3. More information can be found in
Additional file 1.
Results
In the following sections, first the sensitivity and speci-
ficity of ViVaMBC with m = 3 will be investigated using
read sets with known variation. Subsequently, the min-
imum depth of coverage needed for unbiased estimates
will be defined and its overall performance will be com-
pared with three SNP-callers LoFreq [10], V-Phaser2 [12],
and ShoRAH [5]. Finally, ViVaMBC will be illustrated
on a clinical HCV sample where the NS3 region will be
investigated to search for resistance associated mutations
against NS3-4A serine protease inhibitors, telaprevir, and
boceprevir [25].
Sensitivity and specificity
Two different plasmids carrying HCV NS3 amino acids
1 to 181 were mixed in four different proportions. These
plasmids differ only at codon positions 36 and 155. The
mixing proportions were 1:10, 1:50, 1:100, and 1:200 (fastq
files are available at the European Nucleotide Archive,
accession number PRJEB5028; (see Thys K, Verhasselt P,
Reumers J, Verbist BMP, Maes B, Aerssens J. Performance
assessment of the Illumina massively parallel sequencing
platform for deep sequencing analysis of viral minority
variants, submitted for sample preparation). The mix-
tures were sequenced at an average coverage of 86,000.
The plasmid mixture enables the quantification of true
positives (variants at the two codon positions) and the
assessment of the amount of errors that could be cor-
rected by second best base calls (see Additional file 1). The
sensitivity of ViVaMBC was quantified using the two vari-
ant positions. The estimated frequencies, τj, of the real
variants at codon positions 36 and 155 were close to the
mixing proportions (Table 1), suggesting that frequencies
Table 1 Sensitivity of ViVaMBC in plasmid experiment
Mixing prop 36 ATG (%) 155 AAA (%)
1:200 0.45 0.42
1:100 0.92 0.91
1:50 2.28 2.20
1:10 11.04 10.01
Two HCV-plasmids which differ at two codon positions 36 and 155 were
combined in a sample for Illumina deep sequencing at four different mixing
proportions. Their frequencies were estimated with ViVaMBC, which was able to
retrieve codon variants with frequencies up to 0.5%.
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down to 0.5% can be reliably estimated. Codons for the
first 181 aminoacids of the NS3 region were called to
investigate the specificity. No other variants are expected
in this region besides the two variant positions, and hence
only the wild type codons (with frequencies close to 100%)
and the two variants should be detected. The number
of codons reported by ViVaMBC were compared with
the number of codons present in the raw data. In anal-
ogy with mpileup for SNP calling, a pileup table is built
at the codon level where the low-quality parts of the
reads are removed prior to the pileup, called trimming
(see Additional file 1 for more details). The compari-
son with such a pileup table allows to assess the number
of false-positive findings that are actually removed by
ViVaMBC. The pileup resulted in far more than 10,000
codons while ViVaMBC detected only 599 to 841 codons
in the same region (Table 2). This indicates that ViVaMBC
removes the vast majority of false-positive findings. From
the reported codons we removed the wild type codons
with frequencies close to 100% together with the two vari-
ants and investigated the frequencies of the remaining
false-positive findings. The maximum frequency of these
errors is above 1% for the pileup and drops below 1%
for ViVaMBC. The frequency distribution of the errors is
presented in Additional Figure 1, which shows that the
vast amount of frequencies for false positive variants in
ViVaMBC is well below 0.4%. Some false-positive findings
are expected in this frequency range as sample and library
preparation errors are known to occur with frequencies
up to 0.25% [26]. While the discovery of codon variants
at 0.5% and 1% was hampered in the pileup table, it could
be detected with almost 100% specificity using ViVaMBC.
The specific contribution of the second best base error
probabilities in ViVaMBC to these increased sensitivity
and specificity is further explored in Additional file 1.
Minimum depth of coverage
The influence of coverage depth on the accuracy of τ̂j
is investigated using the plasmid data by mixing 1:200
for codon position 155. The original data covered this
position 64,668 times. Datasets with lower coverages are
generated by random sampling a fraction (f=0.1, 0.2,
. . . , 0.8 ,0.9) of the reads from the original dataset. Ten
datasets were generated for each fraction f resulting in
90 datasets with average coverages ranging between 6,463
and 58,185.
ViVaMBC reported two codons for the original dataset
at codon position 155: the wild type codon CGG at a fre-
quency of 99.58% and the variant AAA at 0.42% which is
indicated with the green dotted line in Figure 1. The fre-
quencies (τj) of the variants (hj) for this position reported
by ViVaMBC for each of the 90 re-sampled datasets are
plotted in Figure 1. The true codon variant AAA (green
dots) was detected in all datasets. Averages frequency
estimates over the 10 repeats are indicated with green tri-
angles. Figure 1 indicates that lower coverages reduce the
precision and increase the bias of the estimates. These
deviations start to appear from fraction 0.4, which cor-
responds with coverage around 25,000. The number of
false-positive findings also increases when less reads are
available, but their frequency estimates remain far below
0.4% and the variant at 0.5% can still be discovered at the
lowest coverage.
Comparison with other methods
The performance of ViVaMBC is compared with LoFreq
(v0.5.0) [10], V-Phaser 2 (v2.0) [12], and ShoRAH (v0.8)
[5] (all ran in their default settings) using the previously
described plasmid mixture data. With ShoRAH we were
unable to use the original bam file since some problems
were encountered when extracting the reads from the
desired region. Therefore the ShoRAH results are based
on a bam file with remapped reads against the refer-
ence region of interest. As none of the existing methods
calls variants immediately at the codon level, the eval-
uation is restricted to the ability to detect variants at
individual nucleotide level. The two variant codons dif-
fer at 5 nucleotides from the wild type, so 5 SNPs should
be detected. The comparison is made with ViVaMBC at
the codon level since these variants can be interpreted
immediately with respect to their antiviral drug responses,
which is our primary application domain. The results of
Table 2 Specificity of ViVaMBC in plasmid experiment
Pileup ViVaMBC
Mixing prop N◦ codons Max noise freq (%) N◦ codons Max noise freq (%)
1:200 15,692 1.46 599 0.67
1:100 14,886 1.41 599 0.68
1:50 12,724 1.47 841 0.72
1:10 22,405 1.53 492 0.65
The number of codons in the NS3 are reported after pileup and ViVaMBC. Theoretically, 183(181+2) codons are expected, but far more are reported, especially when
piling up the raw data. The maximum frequency of the false positive codons is presented as well. ViVaMBC is able to reduce these frequencies below 1% while they
reached more than 1% after Pileup. This illustrated that ViVaMBC is able to reduce drastically the number of false-positive findings and to lower the detection limit
above which 100% specificity is expected.
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Figure 1 Influence of coverage depth on the estimation of τj . Datasets with lower coverages are generated by random sampling a fraction
(f = 0.1, 0.2, . . . , 0.8 ,0.9) of the reads from the original dataset. Ten datasets were generated for each fraction f resulting in 90 datasets with average
coverages ranging between 6,463 and 58,185. The reported variants for all re-sampled datasets were plotted and colored according to the
discovered codon. The green dots indicate the true variant and all others are false-positive findings. The average frequency of the true variant
(averaged over the ten random samples) is indicated with triangles. The dotted line is the true frequency as estimated from the original dataset.
Lowering the coverage increases the bias, the variance of the estimate and the number of false-positive findings.
Figure 2 Specificity comparison of ViVaMBC with LoFreq, V-phaser 2 and ShoRAH. The frequencies of all minor variants discovered in the
three mixtures 1:200, 1:100 and 1:50 are plotted for ViVaMBC, LoFreq, V-phaser 2 and ShoRAH. Note that these variants are at the codon level for
ViVaMBC and at the SNP level for the other methods. The false positive variants are indicated with black dots and the true positives with gray crosses.
It is clear that although far more false-positive findings are discovered with ViVaMBC, the distinction with the true positives is more apparent.
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ViVaMBC at the SNP level are reported in Additional
file 1.
The estimated frequencies of the true SNPs for the mix-
ing proportions 1:200, 1:100, and 1:50 are presented in
Table 3 for the existing methods. None of them were
able to retrieve all 5 SNPs at a frequency of 0.5%. LoFreq
could recover them at a frequency of 1% while the others
still showed false-negative findings for the 1:100 mixtures.
ViVaMBC, on the other hand, was able to discover both
codon variants at a frequency of 0.5% and above (Table 1).
The total number of false discoveries over the whole
NS3 region (181 codons of 3bp long) are reported at
the bottom of Table 3 together with the maximum fre-
quency of these false-positive findings. All methods seem
to control the total number of false-positive findingsmuch
better than ViVaMBC, but the frequencies of these false-
positive findings are close to 1% or even above and hamper
the discovery of true variants with similar frequencies.
Despite the higher number of false-positive findings dis-
covered in ViVaMBC, a clear distinction between true-
and false-positive findings can be made for frequencies
around 1%. And with one exception, all false-positive find-
ings fall below 0.4% (see Figure 2). So overall ViVaMBC
has a higher sensitivity and specificity for the discovery of
codon variants at frequencies above 0.5%.
V-phaser 2 and ShoRAH have add-on tools, V-profiler
[27] (v1.0) and localVariants [28] (version january 8th
2014), respectively, to convert lists of SNPs to lists of
codon variants which allows for direct comparison. Local-
Variants is an unpublished tool which is still under devel-
opment and until now we were unable to run it on our
data. At this moment, it failed to define the reading frame
based on the number of stop codons. V-Profiler is devel-
oped as an add-on tool for V-phaser and the output of
V-phaser 2 must be converted to serve as an input for
V-profiler. Both V-profiler and localVariants primarily
focused on 454 data, and only shifted later to Illumina
sequencing. The add-on tools are not fully converted
yet, which makes the translation of the list of SNPs to a
list of codon variants not straightforward. This illustrates
the challenges of retaining linkage information between
neighboring SNPs and the need for variant calling meth-
ods at the codon level.
Clinical sample
The application of ViVaMBC is illustrated here on a clin-
ical HCV sample for which the NS3 amino acids 1 to 181
were sequenced with two sequencing platforms (454 and
Illumina). The error prone GC-region was used for assess-
ing the performance of ViVaMBC but we compared here
the conclusions of the two platforms on the same sample.
As 454 sequencing technology uses a different sequencing
chemistry (see protocol in Thys K, Verhasselt P, Reumers J,
Verbist BMP, Maes B, Aerssens J. Performance assessment
of the Illumina massively parallel sequencing platform
for deep sequencing analysis of viral minority variants,
submitted) it typically results in another error profile.
Variants not discovered with 454 can thus be assumed
to originate from Illumina sequencing errors (and vice
versa). In Figure 3a the estimated frequencies of the
codons discovered by ViVaMBC are plotted against the
corresponding frequencies of the pileup. Codons present
in only one of the two methods are plotted in gray on their
respective axis. Codons that were not present after pil-
ing up the 454 reads were indicated with triangles. Above
0.5% (dotted lines) a good correlation is observed between
the two estimates. A few codons with frequencies above
0.5% in the pileup are not reported by ViVaMBC. These
codons were also absent in 454 reads and can be consid-
ered as false-positive findings in the pileup. On the other
hand, three codons showed a frequency above 1% with
ViVaMBC while they had a lower frequency in the pileup,
one of which was only present in 454. These codons might
be false-positive findings called by ViVaMBC, however
Table 3 Sensitivity and specificity of competingmethods in plasmid experiment
LoFreq V-Phaser2 ShoRAH
SNP (WT) 1:200 1:100 1:50 1:200 1:100 1:50 1:200 1:100 1:50
A (G) / 1.03 2.41 0.59 1.06 2.37 / / 2.22
G (C) 0.54 1.01 2.38 / 0.94 2.33 / / 2.22
A (C) 0.66 1.03 2.16 / / / 0.44* 0.80* 1.78*
A (G) 0.48 0.91 2.10 0.52 1.04 2.11 0.44* 0.80* 1.78*
A (G) / 0.89 2.05 0.48 / 2.07 / / 1.28
N◦false SNPs 3 5 2 19 32 24 4 1 1
Max Freq false SNPs 1.04 1.01 1.02 0.97 1.40 0.72 0.92* 0.5* 0.89
Frequency estimates of the true SNPs after applying the algorithms LoFreq, V-Phaser 2 and ShoRAH on the mixture of plasmids mixed at 1:200, 1:100 and 1:50. Two
SNPs should be present in codon 36, while three SNPs are present in codon 155. In case of ShoRAH, the frequency is estimated from three overlapping windows, but
often the variant is detected in two out of three windows (denoted with *). None of the methods seem to be able to retrieve all 5 SNPs at 0.5%. The bottom rows of the
table report the total number of false SNPs over the whole NS3 region (543 bp long) together with their maximum frequency. The total number of false-positive
findings is very low for all methods but their frequencies rise close to 1% which hamper the distinction of true SNPs from this false-positive findings.
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since it is a clinical sample, it is difficult to assess. Over-
all, ViVaMBC has a very good sensitivity; none of the true
variants discovered with Pileup was missing.
The false discovery rate (FDR), calculated as the num-
ber of false-positive findings (codons not present in 454)
divided by the total number of discovered codons is
investigated for different reporting limits ranging from
0.1% to 1% for both ViVaMBC and pileup (Figure 3b).
ViVaMBC has much lower FDR compared to pileup table
for all reporting limits under investigation. While the
FDR rapidly increases at low frequencies for the pileup,
it remains stable for ViVaMBC up to a frequency of 0.4%
before increasing, which is again in the frequency region
where PCR errors start to occur as well. Moreover, the 454
experiment was limited in its detection due to the limited
depth of coverage.
Additionally, the three methods LoFreq v0.5.0 [10],
V-Phaser 2 v2.0 [12], and ShoRAH v0.8 [5] were ran
Figure 3 Sensitivity and specificity comparison of ViVaMBC with pileup of a clinical HCV sample. a) Comparison of the codon frequencies
after piling up the data (x-axis) with the estimated frequencies of ViVaMBC (y-axis). Codons represented with triangles were absent after 454
sequencing on the same sample and hence assumed to be false-positive findings. Codons colored in grey are present in either one of the two
methods. Frequencies of 0.5% and 0.25% are indicated with dotted and dashed lines respectively. Above 0.5% and even above 0.25% a good
correlation is observed where a few false-positive findings are filtered out using ViVaMBC b) False discovery rates for both ViVaMBC and pileup are
calculated with changing reporting limits. The FDR is higher and increases more rapidly for the pileup.
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on the clinical sample. ShoRAH, however, crashed in
the final stage of the analysis while running the snv.py
script. Hence, Figure 4 only presents the comparison
of the results of ViVaMBC with those of LoFreq and
V-Phaser at SNP level using a barplot representing the
number of reported variants at a particular frequency
range. The shaded region in the bars for ViVaMBC
corresponds to the fraction of codons that were also dis-
covered with 454. Each of the codons reported both by
ViVaMBC and 454, contains at least one SNP that should
be detected by LoFreq and V-Phaser. V-Phaser, how-
ever, reports fewer variants in the majority of the bins,
which indicates that it misses some true positives even
at higher frequencies. LoFreq seems to perform better
and detects all variants up to 1% but is less sensitive at
lower frequencies. ViVaMBC probably reports two false
positives in the frequency bin [1% − 5%], these were
also indicated in Figure 3a, but our method detects far
more true positives especially in low-frequency ranges
as compared to the other methodologies. The results
confirm that codon variants with frequencies down to
0.5% can be reliably detected with ViVaMBC and that
false positives start to appear at lower frequencies. Even
down to 0.25% the proportion of false positives remains
acceptable.
Discussion
Many SNP calling tools have been described in the lit-
erature to correct sequencing errors. Most approaches
are however tailored to call SNPs in human resequencing
projects [29] where SNPs can only be either heterolo-
gous (50%) or homologous (100%). In viral deep sequenc-
ing projects, SNPs present in less than 1% of the reads
are often of interest [30] making the correction much
more challenging. Wilm et al. [10], among others, have
shown that incorporating quality scores improves sen-
sitivity without loss of specificity. The comparison with
existing tools showed, however, that issues with the detec-
tion of low frequency variants with a frequency below
1% in viral populations remains largely unsolved by the
currently available methods. ViVaMBC embeds quality
scores and the second best base calls within amodel-based
clustering approach. The method enables an increase in
sensitivity for variants with frequencies below 1%, while
retaining good specificity above 0.4%. When no sec-
ond best base calls are available, ViVaMBC still shows
an improved sensitivity in comparison with the exist-
ing methodologies. Although the potential of the second
best base calls seemed very promising in the data explo-
ration phase, the additional computational cost of running
the offline base caller is not warranted for our specific
Figure 4 Comparison of LoFreq and V-Phaser with ViVaMBC on clinical sample. Barplot represents the number of reported variants (at SNP or
codon level) by the different methodologies for different frequency bins. The bars are colored according to the method. The shaded region in the
bars for ViVaMBC corresponds to the fraction of codons that were also discovered with 454.
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application. At frequencies below 0.4% we start to see
errors where some of them are presumed as being incor-
porated during sample and library preparation. These
artificial mutations cannot be identified as errors because
the base substitutions are passed to all sequences of the
cluster on the flow cell. Hence, these sample and library
preparation errors form the limit for detection since only
sequencing errors can be corrected with ViVaMBC. To
obtain excellent sensitivity and specificity, samples need
to be sequenced deep enough. When coverage falls below
25,000 the number of false-positive findings increases
and the frequency estimates become biased. Furthermore,
ViVaMBC is one of the first tools that calls variants at the
codon level, which is particularly of interest in virology
applications where drug-target regions are investigated
for resistance-associated amino acid mutations.
The current version of ViVaMBC assumes that each of
the n reads covers the entire window of m nucleotides.
In practice, many reads cover only partially the window.
Although these reads are currently ignored by our method
it has a fairly low impact on the results as variant calling is
done at the codon levelm = 3. Ignoring reads can become
problematic when larger window sizesm are of interest. If
one assumesmissingness completely at random, the likeli-
hood approach could be continued with the observed data
only. The method only has to be adapted to work with
unbalanced data; not all reads will have the same length
m. Let vil denote an indicator which is vil = 1 if read i has
a call at position l and zero otherwise. The density fj in (1)
and (2) become
fj(ri, si) =
m∏
l=1
fj(ril, sil)vil
=
m∏
l=1
[
θ
I(ril=hjl)
ril θ
I(sil=hjl)
sil θ
(1−I(ril=hjl))(1−I(sil=hjl))
oil
]vil
.
(9)
Subsequently, the complete data log-likelihood (6)
becomes
l = log L =
n∑
i=1
k∑
j=1
zij
{
log τj +
m∑
l=1
vil
[
I(r)ijl log θril
+ I(s)ijl log θsil +
(
1 − I(r)ijl
) (
1 − I(s)ijl
)
log θoil
]}
.
(10)
We successfully ran ViVaMBC for a number of HCV-
clinical samples where the whole NS3 region is assessed.
Investigation of the reported codons will help us to dis-
cover mutations associated to resistance against protease
inhibitors and to establish the clinical relevance of resis-
tance associated mutations [31]. While ViVaMBC is espe-
cially developed for virology applications it might be also
applicable in targeted sequencing of cancer associated
genes where one wants to uncover the tumor-population
heterogeneity. These targeted cancer panels investigate
again coding regions, hence working at the codon level
makes absolutely sense here.
Conclusion
ViVaMBC is proposed for identifying variants at the
codon level within a viral population using Illumina
sequencing. The parameters τj and hj define the local
viral population and are inferred given the observed data.
We demonstrated here a superb sensitivity of ViVaMBC
while keeping the frequencies of the false-positive find-
ings below 0.4% when an average coverage of 25,000 is
reached. The strength of the method lies in modeling
the error probabilities, based on the quality scores, which
enables to correct a large fraction of the mismatch bases
incorporated during the sequencing process. When no
second best base calls are available, ViVaMBC can be run
without them while it still provides an optimal sensitivity
when reporting limits of 0.5% are applied. The technical
constraints like PCR errors start to form the bottleneck
for low-frequency variant detection.
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